Established in May 1998, Wicresoft Medical Devices (Shanghai) Group Limited is a leading developer, manufacturer and marketer of medical devices in the PRC, specializing in minimally invasive interventional products for the treatment of vascular diseases and lesions. Listed on the Stock Exchange of Hong Kong in September 2010 (Stock Code: 00853), the Group is a major supplier of cardiovascular and other vascular devices as well as diabetic devices, with its main product being the second generation cobalt-chromium alloy drug-eluting stent, Firebird 2. The Group also supplies other vascular stents, which are used for the treatment of vascular diseases and disorders in other parts of the body. The Group also sells extremely small intracranial stents, flexible stents to promote blood flow in cerebral vessels, and coated stents used in surgical procedures. Wicresoft's products are used in over 1,100 hospitals in the PRC and some of its products are exported outside the PRC to over 20 countries in the Asia Pacific region (excluding the PRC), South America and Europe.